Aditxt, Inc. (ADTX) |
|
1.36 -0.1 (-6.85%)
|
01-27 15:59 |
|
Open: |
1.45 |
Pre. Close: |
1.46 |
|
High:
|
1.5 |
Low:
|
1.3 |
|
Volume:
|
130,311 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:18 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.78 One year: 2.16 |
| Support: |
Support1: 1 Support2: 0.83 |
| Resistance: |
Resistance1: 1.52 Resistance2: 1.85 |
| Pivot: |
1.4 |
| Moving Average: |
MA(5): 1.46 MA(20): 1.39 
MA(100): 2.77 MA(250): 9.52 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 58.9 %D(3): 60.8 |
| RSI: |
RSI(14): 45.6 |
| 52-week: |
High: 28.48 Low: 0.13 |
| Average Vol(K): |
3-Month: 214 (K) 10-Days: 203 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADTX ] has closed above bottom band by 34.9%. Bollinger Bands are 90.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Low:
|
1.28 - 1.29 |
1.29 - 1.3 |
|
Close:
|
1.35 - 1.36 |
1.36 - 1.37 |
|
Company Description |
|
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia. |
Headline News |
Mon, 23 Jan 2023
Is Aditxt Inc (ADTX) a Winner in the Biotechnology Industry? - InvestorsObserver
Fri, 20 Jan 2023
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal ... - StreetInsider.com
Thu, 12 Jan 2023
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock? - Nasdaq
Tue, 03 Jan 2023
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms ... - StreetInsider.com
Tue, 03 Jan 2023
Health Care Sector Update for 01/03/2023: HSTM, ADTX, IMVT - Nasdaq
Fri, 21 Oct 2022
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
3.93e+006 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
97 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.637e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-3 |
|
Return on Assets (ttm)
|
138.2 |
|
Return on Equity (ttm)
|
-86.4 |
|
Qtrly Rev. Growth
|
853150 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-247.53 |
|
EBITDA (p.s.)
|
19744.5 |
|
Qtrly Earnings Growth
|
-1.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.54 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
82350 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
